Site Search

1. 141.
   GENETICS

   At 10^6 viral copies/mL, pre-nuclease treatment increased viral reads from 0.03% of total reads (445 reads) with no treatment to 3.1% (45,517 reads). ScriptSeq and TruSeq ... protocols generated comparable percentages of 0.07% (2,928 reads) and 0.08% (1,410 reads) HIV reads, ... pre-nuclease treatment yielded 1.68% (27,173 reads), 0.28% (3,762 reads) and 0.002

   https://www.amp.org/AMP/assets/File/awards/technologist/WinningTech_Award_Abstra...
2. 142.
   AMP/assets/AMPReconsiderationRequest-Dec2018-FINAL.pdf?pass=39

   MolPath, level 9) x 50%. 2. Crosswalk to code 81162 (BRCA1, ... and full duplication/deletion analysis) x 80% of 50% of 81162 (i.e., (80% (81162 x 50%)) Panel Recommendation: A majority (seven votes) ... Tier 2 MolPath, level 9) x 50% and one member recommended a crosswalk to ... Tier 2 MolPath, level 9) x 50%, as code 81165 involves sequencing of approximately

   https://www.amp.org/AMP/assets/AMPReconsiderationRequest-Dec2018-FINAL.pdf?pass=...
3. 143.
   Microsoft PowerPoint - Phillips Webinar Snyder Oct 2016 (002) [Read-Only]

   Mystery Diseases • 0.4% of live births • 8% of adults have genetic disorder ... mRNA Exon1 Exon2 Exon3 Exome = 1.5% of Human DNA Exome Capture & Sequencing ... identifying causative mutations is ~30% 2) Information not always directly ... 100 120 0 60 120 % of activity Time (minutes) Effects ... 140 160 180 200 220 % of activity * * * + WT Dominant negative

   https://www.amp.org/AMP/assets/File/education/ocw/Handout_PhillipsWebinarSnyderO...
4. 144.
   AMP/assets/File/annualreports/AMP16_AnnualReport_001.pdf?pass=95

   Medical Centers (42%) Commercial Reference Labs (12%) Community Hospital Labs (8%) Government (3%) NGOs (6%) Industry (21.5%) Other (7.5%) AMP MEMBERS BY DEGREE: PhD 854 (36%) MD 994 (42%) Other 522 (22%) A S S O C I A T I O N F O R M O L E C U L A R P A T H O L O G Y 10 2 0 1 6 A N N U A L R E P O R T International E D U C A T I O N I N I T I A T I V E S

   https://www.amp.org/AMP/assets/File/annualreports/AMP16_AnnualReport_001.pdf?pas...
5. 145.
   AMP/assets/File/annualreports/AnnualReport_2017.pdf?pass=88

   SALT LAKE CITY, UT.. . 2,201 AMP MEMBERS WORK IN: Academic Medical Centers (44%) Commercial Reference Labs (12%) Community Hospital Labs (8%) Government (3%) NGOs (6%) Industry (23%) Other (4%) AMP MEMBERS BY DEGREE: PhD 834 (34.5%) MD 1022 (42.2%) Other 561 (23.3%) 2017 Global Congress on Molecular Pathology Organizing Committee members and International

   https://www.amp.org/AMP/assets/File/annualreports/AnnualReport_2017.pdf?pass=88
6. 146.
   AMP/assets/File/education/MIMP/YIA_Winning_Abstracts_2025.pdf?pass=90

   Carriers of hypomorphic variants had a 2.49-fold (95% CI 1.12 to 5.55) increased risk for ... the 33 persons with proviral sequencing, 12 (36%) started LAI CAB/RPV, and 17 (52% ... process, proviral sequencing was limited to 15% of LAI CAB/RPV referrals and, when ... p = 0.0054). In our study set, 21% of wild-type and 44% of mutated ARID1A EC had ARID1A protein

   https://www.amp.org/AMP/assets/File/education/MIMP/YIA_Winning_Abstracts_2025.pd...
7. 147.
   AMP/assets/File/Winning_Abstracts_2019.pdf?pass=75

   10%. The specimen types included formalin- ... least 800X coverage. The results were 100% concordant with orthogonal tests across all specimen ... detected variants with VAF >2.5% in samples where the input DNA ... flat in a 37 C, 5% CO2 incubator, allowing the buccal cells ... showed an overall concordance of 57% to 70% depending on choice of interpretive criteria

   https://www.amp.org/AMP/assets/File/Winning_Abstracts_2019.pdf?pass=75
8. 148.
   GENETICS

   Coriell control DNA cell lines at 185 loci was 99.58% and 98.34%, respectively. A monthly QC plate ... samples have been retested, with 98.67% concordance across all loci and 100% concordance for CYP2C19 variants. Observed ... provide results in >95% of patient samples analyzed on ... causes allograft loss in approximately 5% of renal transplant patients. Risk of

   https://www.amp.org/AMP/assets/File/awards/technologist/Tech_Award_WinningAbstra...
9. 149.
   AMP/assets/File/education/case-studies/0422_48-52_AMPcase-Cao_reprint-lowres.pdf...

   Clinical data on case reports with ETV6/FLT3 fusionLiteratureAge/genderDiagnosisEosinophilia %WBCGenetic testingBreakpointsResponse to ... lymphoma (T-LBL)30.9%Karyotyping, MPseqIn-frame fusion ... FMyeloproliferative neoplasm (MPN)54%Karyotype, FISH, RT-PCR ... lymphoma (PTCL)24%Karyotype, FISH, RT- ... cell lymphoblastic lymphoma22%Karyotype, FISH, RT

   https://www.amp.org/AMP/assets/File/education/case-studies/0422_48-52_AMPcase-Ca...
10. 150.
    AMP/assets/File/clinical-practice/0923_38-39_AMPcase-PalathingalBava-reprint_HighR...

    Primary tumor PC c.853G>A, p.Gly285Lys (AF: 20%); c.637C>T, p.Arg213* (AF: 20%) 0/0 MP c.853G>A, p.Gly285Lys (AF: 11%); c.637C>T, p.Arg213* (AF: 10%) c.3313+1G>A (AF: 5%) 0/1 Recurrent tumor c.637C>T, p.Arg213* (AF: 40%); c.281C>A, p.Ser94* (AF: 18%) c.2155G>T, p.Gly719Cys (AF: 6%) 11/88 PC and MP: papillary component and

    https://www.amp.org/AMP/assets/File/clinical-practice/0923_38-39_AMPcase-Palathi...